Table 6.
Summary of current areas of research.
| Type of Therapy | Study/Agent | Dose/Target | Results | Trial ID |
|---|---|---|---|---|
| Radiotherapy | WHO grade II GTR meningiomas w/adjuvant RT | 54 Gy in 1.8 Gy per fraction | -- | NCT04127760 |
| 59.4 Gy in 33 fractions of 1.8 Gy each | -- | NCT03180268 | ||
| 60 Gy in 30 fractions | -- | ISRCTN71502099 | ||
| 54 Gy in 30 fractions of 1.8 Gy each | 3-year PFS = 98.3% 3-year OS = 96% |
NCT00895622 (RTOG 0539) | ||
| 60 Gy in 30 fractions | 3-year PFS = 88.7% 3-year OS = 98.2% |
NCT00626730 (EORTC 22042-26042) |
||
| Chemotherapy | Vismodegib GSK2256098 |
SMO FAK |
-- | NCT02523014 |
| Selumetinib | MEK pathway | -- | NCT03095248 | |
| Ribociclib | CDK-p16-Rb pathway | -- | NCT02933736 | |
| Everolimus | mTOR-pathway | -- | NCT01880749 NCT01419639 | |
| Everolimus + Octreotide | mTOR + SSTR2A | 6-month PFS = 55% 6-month OS = 90% 12-month OS = 75% |
NCT02333565 (CEVOREM) | |
| Vistusertib (AZD2014) | mTOR-pathway | -- | NCT03071874 | |
| 6-month PFS = 88.9% Decrease in tumor volume of at least 20% = 5.6% |
NCT02831257 | |||
| Alpelisib Trametinib |
Pi3Kα inhibitor MEK inhibitor |
-- | NCT03631953 | |
| Immunotherapy | Nivolumab | PD-1 | -- |
NCT02648997 NCT03173950 |
| Nivolumab w/Multi-Fraction SRS ± Ipilimumab | PD-1 ± CTLA-4 | -- | NCT03604978 | |
| Pembrolizumab | PD-1 | -- |
NCT03279692 NCT03016091 |
|
| Pembrolizumab w/SRS | PD-1 | -- | NCT04659811 | |
| Avelumab w/Proton radiotherapy | PD-L1 | -- | NCT03267836 |